Studies on the anti-diabetic and hypolipidemic potentials of mangiferin (xanthone glucoside)in streptozotocin-induced type 1 and type 2 diabetic model rats
Studies on the anti-diabetic and hypolipidemic potentials of mangiferin (xanthone glucoside)in streptozotocin-induced type 1 and type 2 diabetic model rats
- International Journal of Advances in Pharmaceutical Sciences, 1(1), p.75-85, 2010 .
Context: Mangifera indica (Anacardiaceae)stem bark contains a rich content of mangiferin and is used traditionally in Indian Ayurvedic system to treat diabetes. Purpose of the study: To investigate anti-diabetic and hypolipidemic effects of mangiferin in type 1 and type 2 diabetic rats models. Streptozotocin was used to induce type 1 and type 2 diabetic rats. Mangiferin (at a dose 10 and 20mg/kg)was administrated intra-peritoneally in type 1 and type 2 diabetic rats daily up to 30 days. Biochemical parameters notably fasting blood sugar, total cholesterol, triglycerides, low-density lipoprotein, very low-density lipoprotein and high-density lipoprotein were estimated. In addition, in vitro alpha amylase and alpha glucosidase inhibitory effects of mangiferin were performed and IC50 values were determined. Results: Mangiferin exhibited significant (P<0.05)anti-diabetic as well as hypolipidemic effects by lowering FBS, TC, TG, LDL, and VLDL levels; but also with elevation of HDL level in type 2 diabetic model rats. In addition, mangiferin showed appreciable alpha amylase inhibitory effect (IC50 value 74.35±1.9µg/ml)and alpha glucosidase inhibitory effect (IC50 41.88±3.9µg/ml)when compared with standard drug acarbose (IC50 83.33±1.2µg/ml). Conclusions: Mangiferin showed anti-diabetic as well as hypolipidemic potentials in type 2 diabetic model rats. Therefore, mangiferin possess beneficial effects in the management of type 2 diabetes with hyperlipidemia.
ACARBOSE
ALPHA GLUCOSIDASE
AMYLASE
CHOLESTEROL
GLIBENCLAMIDE
GLUCOSE
HIGH DENSITY LIPOPROTEIN
LOW DENSITY LIPOPROTEIN
MANGIFERIN
RECOMBINANT HUMAN INSULIN
TRIACYLGLYCEROL
VERY LOW DENSITY LIPOPROTEIN
Context: Mangifera indica (Anacardiaceae)stem bark contains a rich content of mangiferin and is used traditionally in Indian Ayurvedic system to treat diabetes. Purpose of the study: To investigate anti-diabetic and hypolipidemic effects of mangiferin in type 1 and type 2 diabetic rats models. Streptozotocin was used to induce type 1 and type 2 diabetic rats. Mangiferin (at a dose 10 and 20mg/kg)was administrated intra-peritoneally in type 1 and type 2 diabetic rats daily up to 30 days. Biochemical parameters notably fasting blood sugar, total cholesterol, triglycerides, low-density lipoprotein, very low-density lipoprotein and high-density lipoprotein were estimated. In addition, in vitro alpha amylase and alpha glucosidase inhibitory effects of mangiferin were performed and IC50 values were determined. Results: Mangiferin exhibited significant (P<0.05)anti-diabetic as well as hypolipidemic effects by lowering FBS, TC, TG, LDL, and VLDL levels; but also with elevation of HDL level in type 2 diabetic model rats. In addition, mangiferin showed appreciable alpha amylase inhibitory effect (IC50 value 74.35±1.9µg/ml)and alpha glucosidase inhibitory effect (IC50 41.88±3.9µg/ml)when compared with standard drug acarbose (IC50 83.33±1.2µg/ml). Conclusions: Mangiferin showed anti-diabetic as well as hypolipidemic potentials in type 2 diabetic model rats. Therefore, mangiferin possess beneficial effects in the management of type 2 diabetes with hyperlipidemia.
ACARBOSE
ALPHA GLUCOSIDASE
AMYLASE
CHOLESTEROL
GLIBENCLAMIDE
GLUCOSE
HIGH DENSITY LIPOPROTEIN
LOW DENSITY LIPOPROTEIN
MANGIFERIN
RECOMBINANT HUMAN INSULIN
TRIACYLGLYCEROL
VERY LOW DENSITY LIPOPROTEIN